Sage Journals: Discover world-class research

Retricted access

Research article

First published 2016-7

HR Positioning—A Matter of National Culture? Facts from Hungary

Katharina Thill, Barbara Covarrubias Venegas, József Poór

Business Perspectives and Research

Open access

Research article

First published 2024

Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Qingyuan Zhang, Pin Zhang, Min Yan [...]

Therapeutic Advances in Medical Oncology

Retricted access

Editorial

First published 1972-2

Position Statement on HR I

Ellen P. Manser

Families in Society: The Journal of Contemporary Social Services

Open access

Research article

First published 2025-4

Exploring the HR analyst position around the globe

Rene Arseneault, Jialiang Yang

International Journal of Cross Cultural Management

Open access

Research article

First published 2024

HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan [...]

Therapeutic Advances in Medical Oncology

Retricted access

Research article

First published 2026

Predictive Value of Magee Equation 3 for Tumor and Axillary Response to Neoadjuvant Chemotherapy in HR-Positive,HER2-Negative Breast Cancer

Mustafa Onur Beştaş, Erkan Güler, Ahmet Dağ [...]

The American Surgeon™

Retricted access

Research article

First published 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Chris Larck, Joseph B Elmes, R. Wesley Haynes [...]

Journal of Oncology Pharmacy Practice

Open access

Review article

First published 2015

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive,Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Adam M. Brufsky

Clinical Medicine Insights: Oncology

Open access

Research article

First published 2025

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

Bora Lim, Angela Marx, Megumi Kai [...]

Therapeutic Advances in Medical Oncology

Open access

Review article

First published 2023

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

Mark Pegram, Richard Pietras, Chau T. Dang [...]

Therapeutic Advances in Medical Oncology

Search results